Table 2. Evaluation of cell surface expression of TRAIL receptors before and after α-TOS treatment in MM and mesothelial cells.
|
DR4 |
DR5 |
DcR1 |
DcR2 |
|||||
|---|---|---|---|---|---|---|---|---|
| Cell type | Ctrl | α-TOS | Ctrl | α-TOS | Ctrl | α-TOS | Ctrl | α-TOS |
| MM-B1 | 2.5±0.30 | 3.1±0.25 | 4.3±0.50 | 5.9±0.72 | 1.2±0.20 | 1.2±0.21 | 1.0±0.11 | 1.0±0.14 |
| Meso-2 | 1.6±0.25 | 2.4±0.32 | 2.0±0.12 | 6.7±0.52 | 1.1±0.21 | 1.1±0.35 | 1.0±0.10 | 1.0±0.12 |
| Ist-Mes | 1.7±0.54 | 2.0±0.38 | 3.6±0.61 | 4.3±0.52 | 1.3±0.20 | 1.1±0.22 | 1.0±0.11 | 1.0±0.09 |
| Met-5A | 1.9±0.31 | 2.2±0.41 | 1.7±0.46 | 1.8±0.33 | 1.0±0.05 | 1.0±0.06 | 1.0±0.14 | 1.2±0.08 |
The expression of TRAIL receptors was evaluated by flow cytometry before (Ctrl) and after treatment with α-TOS (30 μM, 16 h) in MM and mesothelial cells. The values represent the fluorescence intensity of the receptors normalised for a blank incubated with an irrelevant primary antibody. Data are expressed as mean±s.d. from three independent experiments and statistical differences between controls vs α-TOS treatment are bold, P<0.005.